Journal of International Psychiatry

[Abstract] Objective To explore the effect of different doses of sertraline combined with ziprasidone in the treatment of schizophrenia with depressive symptoms. Methods 160 schizophrenic patients with depressive symptoms admitted from May 2018 to May 2021 were included in the study and divided into group A (n=60), group B (n=50) and group C (n=50). Group A adopted the combination of low-dose sertraline and low-dose ziprasidone, Group B adopted the combination of low-dose sertraline and conventional ziprasidone, and Group C adopted the combination of conventional sertraline and low-dose ziprasidone, with a period of 3 months. Compare the changes of clinical symptoms [positive and negative symptoms scale (PANSS)], depression level [Hamilton depression scale (HAMD)], cognitive function [Montelli cognitive assessment scale (MoCA)] and quality of life [WHO short form of quality of life scale (WHOQOL-BREF)] of the three groups of patients before and after treatment, and count the occurrence of adverse drug reactions of the three groups of patients. Results After treatment, the scores of MoCA and WHOQOL-BREF in group A were significantly higher than those in group B and group C (P<0.05); The scores of PANSS and HAMD in group A were significantly lower than those in group B and group C (P<0.05); There was no significant difference in the scores of PANSS, HAMD, MoCA, WHOQOL-BREF and the occurrence of adverse drug reactions among the patients in group B and group C (P>0.05). Conclusion The combination of low-dose sertraline and low-dose ziprasidone can effectively improve the clinical symptoms, depression level, cognitive function and quality of life of schizophrenic patients with depressive symptoms.

[Key words] Schizophrenia; Sertraline; Ziprasidone; Depression level; Cognitive function